MARKET

NTRA

NTRA

Natera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

126.36
+5.99
+4.98%
After Hours: 126.25 -0.11 -0.09% 19:58 09/17 EDT
OPEN
120.99
PREV CLOSE
120.37
HIGH
126.52
LOW
119.80
VOLUME
1.22M
TURNOVER
--
52 WEEK HIGH
127.19
52 WEEK LOW
58.65
MARKET CAP
11.85B
P/E (TTM)
-34.4700
1D
5D
1M
3M
1Y
5Y
BRIEF-Natera Releases New Clinical Data At ESMO 2021 In Gastroesophageal Cancer And Uveal Melanoma
reuters.com · 18h ago
Natera Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Melanoma
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, today announced new data being presented by the company and its collaborators on the use of the Signatera® personalized molecular residual disease (MRD) technology at the 2021 European Society...
PR Newswire · 18h ago
CEO And President Of Natera Trades $12.01 Million In Company Stock
Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on S...
Benzinga · 4d ago
Natera Inc (NTRA) CEO AND PRESIDENT Steven Leonard Chapman Sold $10.9 million of Shares
GuruFocus News · 6d ago
Natera Launches Prospera™ Kidney with Quantification to Further Improve Test Performance, Demonstrating Commitment to Innovation in Transplantation
Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA (cfDNA) testing, today announced the launch of Prospera with Quantification, the only cfDNA test for kidney rejection that provides three values — the quantity of ...
PR Newswire · 09/09 12:33
Natera's Signatera® Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-III Colon Cancer
/PRNewswire/ -- (NASDAQ: NTRA) a leader in transforming care through genetic and cell-free DNA testing, today announced an agreement with NRG Oncology, a National Cancer Institute (NCI)-funded group, to use the Signatera personalized molecular residual dis...
PR Newswire - PRF · 09/07 10:03
BRIEF-Natera Announces Launch Of Prospera Heart Transplant Assessment Test
reuters.com · 08/31 12:34
Natera Announces the Validation and Launch of the Prospera™ Heart Transplant Assessment Test
Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA (cfDNA) testing, today announced the validation and clinical availability of its Prospera Heart transplant assessment test for heart transplant recipients. This la...
PR Newswire · 08/31 12:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NTRA. Analyze the recent business situations of Natera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NTRA stock price target is 150.11 with a high estimate of 160.00 and a low estimate of 135.00.
EPS
Institutional Holdings
Institutions: 413
Institutional Holdings: 103.47M
% Owned: 110.32%
Shares Outstanding: 93.78M
TypeInstitutionsShares
Increased
114
6.15M
New
67
8.10M
Decreased
117
8.96M
Sold Out
47
1.22M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.65%
Key Executives
Chairman/Co-Founder/Director
Matthew Rabinowitz
President/Chief Executive Officer/Director
Steven Chapman
Co-Founder/Director
Jonathan Sheena
Chief Financial Officer/IR Contact Officer
Michael Brophy
Chief Operating Officer
Robert Schueren
Lead Director/Independent Director
Roelof Botha
Independent Director
Roy Baynes
Independent Director
Monica Bertagnolli
Independent Director
Rowan Chapman
Independent Director
Todd Cozzens
Independent Director
James Healy
Independent Director
Gail Marcus
Independent Director
Herman Rosenman
No Data
About NTRA
Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).

Webull offers kinds of Natera Inc stock information, including NASDAQ:NTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTRA stock methods without spending real money on the virtual paper trading platform.